Thursday, 27 January 2022

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

Janssen's 'queue jumping' plan

Posted December 6 2021 PM

Australians are waiting longer for the reimbursement of new medicines than many of their overseas counterparts, with the average new medicine taking more than a year to get reimbursed, but the Covid pandemic demonstrated it doesn't have to be this way.

A new report by Johnson & Johnson, Getting Australia to the Front of the Queue, suggests changes to the Health Technology Assessment process and the PBAC remit, citing the speed with which COVID-19 vaccines were brought to market as an alternative to the current time frames.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.